Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Carcinoma × fludarabine × Clear all

Phase

Phase 1 4 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 4 Recurrence 3 Ovarian Neoplasms 3 Burkitt Lymphoma 3 Nasopharyngeal Carcinoma 2 Lymphoma, T-Cell 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Solid Tumors 1 Solid Cancer 1 Small Cell Lung Carcinoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroblastoma 1 Neoplasms, Plasma Cell 1 Neoplasms, Neuroepithelial 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, B-Cell 1 Leukemia, T-Cell 1 Leukemia 1 High-risk Plasma Cell Neoplasms 1 Epstein-Barr Virus Infections 1 Carcinoma, Hepatocellular 1 Carcinoma 1 CD19-positive Relapsed or Refractory B-cell Malignancies 1 Advanced Solid Tumor 1

Interventions

fludarabine 1 aldesleukin 1 adavosertib 1 Oncolytic Virotherapy 1 Interleukin-2 1 Cyclophosphamide 1 Clinical Protocols 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05141474 2024-11-07

NEXTGENTIL-ACT

Vall d'Hebron Institute of Oncology

Phase EARLY_PHASE1 Recruiting

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡